Yan Leyfman/LinkedIn
Apr 14, 2026, 13:09
Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, Medical Correspondent at OncLive, shared on LinkedIn:
”Thank you to Cancer Network for the feature.
Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease
Gene editing has moved from concept to clinic.
By leveraging CRISPR to reactivate fetal hemoglobin, we’re no longer just managing Sickle Cell Disease – we’re aiming to rewrite its biology.
Targeting regulators like BCL11A is elegant.
Making it durable, scalable, and accessible is the real challenge.
This is where curative intent becomes tangible.
Worth the read if you’re following where ‘hematology and gene therapy’ is heading.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial
-
Oct 20, 2026, 03:37Rucha Patil: Scaling POC Diagnostics for Haemophilia A and VWD Across India
-
Oct 20, 2026, 03:31Zena Vexler: Targeting Neutrophil Elastase and NETosis to Mitigate Infection-Triggered Childhood Stroke
-
Oct 20, 2026, 03:24Chaza Alaji: Diagnosing Protein C and Protein S Deficiency
-
Oct 20, 2026, 03:24Mou Nandi: How Maternal Health During Pregnancy May Shape Infant Development